Annual Scientific Meeting 2018
|
|
- Grace McDonald
- 5 years ago
- Views:
Transcription
1 Annual Scientific Meeting 2018 Reported by HYY Kwong, HL Lo, SH Ng, PY Ngan, W Ngan, HW Wong, WF Wu Date: June 2018 Venue: Sheraton Hong Kong Hotel & Towers, Tsim Sha Tsui, Hong Kong Organiser: Hong Kong Society of Dermatology and Venereology Therapy of pemphigus I: the Japanese guideline Speaker: Jun Yamagami Department of Dermatology, School of Medicine, Keio University, Japan Updated guidelines were published in 2010 in order to improve the quality of management of pemphigus. The speaker shared his experience about fundamental treatment strategy against pemphigus based on the guidelines. The general goal in the treatment of pemphigus is to achieve and maintain remission. Remission is defined as the absence of new or established lesions using minimal therapy, in most cases less than 10 mg prednisone daily and/ or minimal adjuvant therapy. In order to accomplish this goal, adequate initial therapy is of utmost importance as inadequate treatment may result in disease recurrence during steroid tapering. The initial therapy typically consists of high dose oral prednisone. Disease activity should be evaluated according to clinical symptoms and scoring system like the Pemphigus Disease Area Index. If insufficient therapeutic effects are noted after two weeks of initial treatment, additional therapies such as high-dose intravenous immunoglobulin therapy, plasma exchange or pulse steroid therapy should be considered. Once the disease is under control, tapering of steroid should be initiated and maintenance therapy with minimal dose of steroid and/or immunosuppressive agent should be continued. The serum antibody titre such as the desmoglein ELISA index is useful for the assessment of disease activity in the maintenance stage. Adequate initial therapy is important for prompt control of pemphigus and to prevent early disease recurrence during tapering of steroid. Maintenance therapy consists of minimal dosage of oral steroid and/or immunosuppressive agent. Therapy of pemphigus II: newer modalities Speaker: John R Stanley Department of Dermatology, University of Pennsylvania, USA The basic principle of therapy for pemphigus is to eliminate the autoantibodies and its production by B cells which may lead to a cure. Current therapies for pemphigus such as prednisone, azathioprine, mycophenolate and IVIG decrease autoantibodies in a non-targeted way. These immunosuppressive therapies rarely
2 permanently eliminate the pathogenic autoantibodies. Rituximab is an anti-cd20 monoclonal antibody that eliminates existing B cells except stem B-cells. The regenerated repertoire from stem B-cells do not develop autoantibodies and hence often leads to a permanent remission of pemphigus. A higher dose and earlier therapy are more effective. Previous study showed that it can be used as primary therapy for pemphigus with promising results. An even specific targeted therapy that eliminates only anti-desmoglein B cells by using engineered chimeric autoantibody receptor (CAAR) T cells is being tested in preclinical therapy. It may be highly effective in permanent elimination of autoantibodies and hence lead to disease cure. Treatment of pemphigus disease should aim to eliminate autoantibodies which often leads to a cure. Promising new modalities of targeted treatment including rituximab (anti-cd20 monoclonal antibody) and chimeric autoantibody receptor (CAAR) T cells may improve the clinical outcomes of pemphigus in future. Anticancer drug-induced skin reactions: clinical manifestations and management Speaker: Wen-Hung Chung Chang Gung Memorial Hospital, Taiwan Toxic erythema of chemotherapy is commonly due to cytarabine, doxorubicin and fluorouracil. This is treated by drug discontinuation and supportive care. For example, papulopustular eruptions which are usually due to epidermal growth factor receptor inhibitors can be managed by use of sunscreens, emollients, topical steroids and doxycycline. Hand foot skin reaction is typically due to multikinase inhibitors (i.e. sorafebin and sunitinib). Risk factors include elderly female patients with history of total body radiation. Ice packing, topical steroids, urea cream, NSAID and pyridoxine are recommended. Immunotherapy-induced side effects are due to reduced peripheral tissue tolerance. They are usually low grade and involve the skin (predominantly manifesting as a psoriasiform and lichenoid dermatitis) and has a good prognosis. Systemic steroids can be used for the abnormal T cell reaction. Occasionally, toxic epidermal necrolysis can occur. Classical chemotherapy side effects include toxic erythema of chemotherapy. With the advent of newer targeted therapy and immunotherapy, the spectrum of side effects has changed. Clinicians therefore need to keep update with latest developments. Hidradenitis suppurativa Speaker: Erin McMeniman Princess Alexandra Hospital South East Dermatology, Hidradenitis Suppurativa (HS) is a recurrent autoimmune disease due to follicular occlusion and increased cytokines in the skin. Contrary to conventional belief, it is neither infective nor apocrine gland-related. It usually presents as nodules or abscesses with sinus tract formation in the axillary, mammillary and gluteal regions. Treatments include using antiseptics to prevent secondary infection, topical clindamycin and oral antibiotics to reduce inflammation, and surgery. In the recent years, the arrival of biological therapy has revolutionised the care of HS.
3 HS is an autoimmune disease with increased skin cytokines. Apart from surgical treatment, medical treatments which target these cytokines are helpful (i.e. TNF alpha blockade by biological therapy). Mycoplasma genitalium in female Speaker: David A Lewis Western Sydney Sexual Health Center, Western Sydney Local Health District and University of Sydney, Mycoplasma genitalium(mg) has been strongly implicated in non-gonococcal urethritis (NGU), it accounts for 20-35% of non-chlamydial NGU cases in males. It is also found to be significantly associated with urethritis, vaginal discharge, microscopic cervicitis and mucopurulent cervical discharge. However, the association with pelvic inflammatory disease, infertility and ectopic pregnancy is still unclear. There is a need to further investigate the pathogenic role of MG in terms of sequelae, also its pathogenesis and immune activation in both symptomatic and asymptomatic cases. The prevalence of MG was estimated to be 2% in low-risk populations and 7.3% in high-risk populations. Widespread screening with the current commercial nuclei acid amplification test is not recommended in view of the low MG prevalence in most populations. Further prospective studies are needed to determine whether screening and targeted treatment of MG infection in women can reduce the incidence of adverse sequelae and improve reproductive outcomes. Azithromycin-resistant MG is a growing problem in countries using Azithromycin 1g for Chlamydia treatment. Therefore, the 5-day extended 1.5 g Azithromycin regimen is preferred (Azithromycin 500 mg daily for day 1, then 250 mg daily for day 2 to 5). Moxifloxacin should be considered when resistance to Azithromycin is found. Mycoplasma genitalium should be considered in cases of non-gonococcal urethritis, female urethritis, cervicitis and the preferred treatment is the 5-day extended 1.5 g Azithromycin regimen. Antimicrobial resistance and new treatment options for gonorrhea Speaker: David A Lewis Western Sydney Sexual Health Center, Western Sydney Local Health District and University of Sydney, Neisseria gonorrhoeae (NG) has been labelled as one of the microorganisms with a threat level of urgent by CDC in 2013 and one of the pathogens with a high priority for research and development of new antibiotics by WHO in The emergence and transmission of extensively drug resistant NG has been found in the recent decade. The question of whether "old" antimicrobials can be used as "new drugs" was addressed and the choices that were explored included Spectinomycin, Gentamicin, Ciprofloxacin and Fosfomycin. This would be challenging and will need the development of molecular assays that can diagnose NG and predict the susceptibility of these "old" antimicrobial agents. Currently, Ertapenem has been used as a treatment for extensively drug resistant NG. Three potential new drugs have been developed in recent or planned clinical trials, which is Solithromycin, Zoliflodacin and Gepotidacin. Nevertheless, with the current situation, the most important action is to reduce the transmission of gonorrhea and to protect the current drugs that we have by using high doses of Ceftriaxone as monotherapy or as dual therapy with Azithromycin.
4 The important action in the current era is to reduce the transmission of gonorrhea and to correctly use the current drugs that we have high dose Ceftriaxone as monotherapy or dual therapy with Azithromycin. Diagnosis and management of paediatric vascular malformations Speaker: Erin McMeniman Princess Alexandra Hospital South East Dermatology, It may be challenging to diagnose and manage vascular tumours and malformations in infants. The speaker cited the International Society for the Study of Vascular Anomalies (ISSVA) classification to illustrate how the various vascular tumours and malformations can be better differentiated. Some commonly encountered conditions, such as port-wine stain and infantile haemangioma were mentioned by the speaker. Other than diagnosing the vascular conditions, the attending physician should check for any associated developmental anomalies, e.g. the association between port-wine stain and Sturge- Weber syndrome; the association between large segmental haemangioma and PHACES as well as LUMBAR syndromes. For multiple infantile haemangiomas (more than five), one should also screen for any internal organ involvement, especially liver haemangioma. Regarding prognosis, 30% infantile haemangiomas would involute by the age of three years, 50% by the age of five years and 90% by the age of nine years. The lesion may have remnants in the form of fibrofatty tissue and telangiectasia. From a recent Cochrane review in 2018, oral propranolol has replaced systemic steroid as standard of care in the proliferative phase. Topical timolol, wound care and vascular laser may be used as appropriate in superficial haemangiomas. Treatment should be considered when there is airway obstruction, congestive heart failure, bleeding, ulceration, lifelong disfigurement or mental distress for child and family. Treatment of vascular malformations and tumours require a multidisciplinary approach. Oral propranolol has become the standard treatment of infantile haemangioma. Dermatologic reactions to immune checkpoint inhibitors Speaker: Vincent Sibaud Medical Oncology and Dermatology Units, Institut Universitaire du Cancer Toulouse-Oncopole, France Anti-Programmed cell Death protein 1 / anti- Programmed Death-Ligand 1 (anti-pd-1/pd-l1) and Cytotoxic T Lymphocyte Associated protein 4 (CTLA-4) antibodies are gaining spotlight in oncology treatment. The most common immune-related adverse effects (iraes) of these therapeutic agents are cutaneous toxicities. Dermatological iraes appear to be similar for anti-pd-1/pd-l1 and CTLA-4 antibodies. However, the incidence is lower with anti-pd- 1/PD-L1. In melanoma patients undergoing anti-pd-l1 therapy, more than 40% of them have dermatological iraes. The most common iraes is non-specific maculopapular rash with pruritus. Lichenoid dermatitis and psoriasiform dermatitis may also be the manifestation of iraes. Other reported possible iraes include papulopustular rosacea, bullous pemphigoid, eruptive keratoacanthoma/ SCC and Grover's like disease. Mucosal involvement may manifest as SjÖgren-like xerostomia and oral lichenoid reaction. Hair toxicity leading to alopecia areata is also noted.
5 Despite the cutaneous iraes secondary to anti-pd-1/pd-l1 are usually self-limiting, early recognition is important for proper dose adjustment to prevent the more severe iraes. Hitting the target in psoriasis with IL-23 inhibition Speaker: Chin-ho Hong Department of Dermatology and skin Science, University of British Columbia, Canada Interleukin 23 (IL- 23) is an essential key regulatory cytokine that promotes T cell differentiation. The differentiated T cells will further produce TNFα and IL-17. New anti-il 23 blockers are developed to control the upstream pathway of cytokine production. Guselkumab is one of the anti-il- 23 blockers which has shown promising results in phase III studies. It has achieved psoriasis severity index PASI 90 and is superior to adalimumab. The PASI response has been sustained for up to two years. Available biologics range from those that act on effector cytokines to those that act on regulatory cytokines. Newer agents are opening a new era in the treatment of psoriasis. Evidence supporting the efficacy and safety of biologics is growing. New agents such as IL-23 inhibitor guselkumab is emerging with promising result. Clinicopathological relationship between purely cutaneous Rosai- Dorfman disease and IgG4-related skin disease Speaker: Wai-fuk Wu Medical & Health Officer, Social Hygiene Service, Center for Health Protection, Department of Health, Hong Kong Cutaneous Rosai-Dorfman disease with no systemic involvement is a benign histiocytic disorder while IgG4-related skin disease is a fibroinflammatory condition. These two diseases share some overlapping features, but their relationship remains uncertain. This study showed that they should be regarded as two distinct entities after correlating the clinicopathological and immunohistochemical features as a whole. Pure cutaneous Rosai-Dorfman disease and IgG4-related skin disease should be regarded as two distinct entities. Drug-induced severe cutaneous adverse reactions in paediatric population Speaker: Wen-hung Chung Department of Dermatology, Chang Gung Memorial Hospital, Taiwan Drug-induced adverse reactions in children are often associated with mucocutaneous manifestations that mimic viral exanthems and erythema multiforme major. Therefore, the attending physician has to bear in mind the possibilities of drug eruption, Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when encountering maculopapular and morbilliform rash in children.
6 The speaker illustrated use of ALgorithm of Drug causality for Epidermal Necrosis (ALDEN) in assessing possible culprit drugs for paediatric SJS and TEN cases. Based on his study in Taiwan, antibiotics, anticonvulsants and nonsteroidal anti-inflammatory drugs were the most common drugs for SJS/TEN and drug reaction with eosinophilia and systemic symptoms. After identification and withdrawal of the culprit drug, multidisciplinary supportive care should be instituted for SJS/TEN patients, such as thermoregulation, airway protection, fluid balance, nutritional support, pain management, venous thromboembolism prophylaxis, monitoring of infection and psychological support. Intensive care in a burns unit may be required. In the acute stage, the speaker suggested to consider early use of systemic immunomodulatory agents, e.g. corticosteroids, cyclosporine. Skin and mucous membrane treatments should also be continued. Clinical trials of high-dose steroid pulse therapy and other biologic agents in SJS/TENS are ongoing. mucocutaneous PV have anti-dsg1 and anti- Dsg3 antibodies. Therefore, the diagnosis can be made by ELISA assays against Dsg1 and Dsg3. The location of the blisters in pemphigus can also be explained by Dsg compensation. Dsg1 and Dsg3 can compensate for loss of function of the other caused by autoantibodies if they are both present in the same tissue at the same level of epithelium. Regarding treatment, the rapid response to corticosteroids used for disease control may be due to increase in synthesis of Dsgs thus overcoming their depletion by autoantibodies. This process is mediated by STAT3 signalling. Pemphigus blisters are caused by anti-dsg autoantibodies through direct inhibition of cell adhesion. The blister formation is enhanced by signalling pathway. Therapies targeting other signalling pathways may be used to decrease blistering. Though severe cutaneous adverse reactions are uncommon, they can result in severe potential complications. Early diagnosis and timely treatment would reduce the morbidity and mortality. Pathophysiology of pemphigus Speaker: John R Stanley Department of Dermatology, University of Pennsylvania, USA Blisters in the patients with pemphigus are caused by autoantibodies against desmogleins (Dsgs). In general, patients with pemphigus foliaceus (PF) have anti-dsg1 antibodies; patients with mucosal pemphigus vulgaris (PV) have anti-dsg3 antibodies; and patients with Bullous pemphigoid: an updated review Speaker: Jun Yamagami Department of Dermatology, School of Medicine, Keio University, Japan The Japanese government designated "pemphigoid", including bullous pemphigoid (BP), mucous membrane pemphigoid and epidermolysis bullosa acquisita, as nationally occurring intractable disease in Therefore, Japanese guidelines for the management of pemphigoid were published in Similar to pemphigus guidelines, the guidelines for BP has defined maintenance of remission as the treatment goal, and has divided treatment into two stages (initial therapy and maintenance therapy). Unlike pemphigus, during initial treatment of BP, mild, moderate
7 and severe disease are treated differently: Staging of disease severity is by Bullous Pemphigoid Disease Area Index (BPDAI). The guidelines distinguished circumstantial therapies for pemphigoid (not pemphigus), such as superpotent topical steroids, doxycycline and cyclophosphamide. Dipeptidyl peptidase-4 (DDP-4) inhibitors are oral anti-hyperglycaemic drugs used in the treatment of type 2 diabetes mellitus. Cases of BP in patients after taking DDP-4 inhibitors have been reported. DDP-4i-BP patients usually present with the non-inflammatory phenotype of BP, with less erythema than observed in BP patients not on DDP-4 inhibitors. In addition, DDP-4i-BP patients have IgG autoantibodies against full-length BP180 but not against the NC16a domain, which is the main target of autoantibodies in typical BP. The clinical features (less erythema) and IgG autoantibodies against full-length BP180 can be used to diagnose patients with BP caused by DDP-4 inhibitors.
What's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More informationAutoimmune Diseases with Oral Manifestations
Autoimmune Diseases with Oral Manifestations Martin S. Greenberg DDS, FDS RCSEd Professor Emeritus Department of Oral Medicine University of Pennsylvania Disclosure Statement I have no actual or potential
More informationCutaneous Drug Reactions
Cutaneous Drug Reactions Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses
More informationThe objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and
1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship
More informationEmergency Dermatology Dr Melissa Barkham
Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term
More information6. Gonococcal antimicrobial susceptibility
6. Gonococcal antimicrobial susceptibility Key points Gonococcal AMR continues to increase worldwide and could lead to a pandemic of extensively drug-resistant (XDR) N. gonorrhoeae with serious public
More informationReports on Scientific Meeting
Hong Kong J. Dermatol. Venereol. (2017) 25, 138-143 Reports on Scientific Meeting Annual Scientific Meeting 2017 Reported by NM Lau, WH Leung, PY Ngan, CK Wong, LP Wong Date: 24-25 June 2017 Venue: Sheraton
More informationSignificance. Outline and Objectives. S007 Systemic Therapies for Medical Oncology
S007 Systemic Therapies for Medical Oncology Anisha B. Patel, M.D. Assistant Professor, Dermatology UT MD Anderson Cancer Center UT Health Science Center Houston Safety considerations Outline and Objectives
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationDilantin (phenytoin) ROBERT A. SCHWARTZ
Dilantin (phenytoin) ROBERT A. SCHWARTZ Bailey & Galyen Attorney in Charge, Mass Tort Litigation Managing Attorney, Houston 18333 Egret Bay Blvd., Suite 120 Houston, Texas 77058 Toll Free: (866) 715-1529
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationMycoplasma genitalium: An Important Consideration in Male Urethritis DR. ALEXANDRA CARLE
Mycoplasma genitalium: An Important Consideration in Male Urethritis DR. ALEXANDRA CARLE Overview Introduction to Mycoplasma genitalium Audit Objectives Standards Results Reflection AFPHM learning objectives
More informationFuture of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016
A. Yasmine Kirkorian MD Assistant Professor of Dermatology & Pediatrics Children s National Health System George Washington University School of Medicine & Health Sciences Future of Pediatrics: Blisters,
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationAUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE
AUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE Ron Feldman, MD, PhD Assistant Professor of Dermatology Emory University ron.j.feldman@emory.edu Disclosures I have no conflict of interest to
More informationOncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza
Oncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza Dermatologic adverse events of oncologic drugs Grading of Dermatologic Adverse Events (ver 5.0) 5 grades: mild, moderate,
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationManagement of Gonorrhea in Adolescents and Adults in the United States
SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,
More informationFuture clinical trials of targeted therapies for pemphigus
Future clinical trials of targeted therapies for pemphigus Aimee S. Payne, MD, PhD University of Pennsylvania September 17, 2017 Conflicts of interest: Founder of Tycho Therapeu9cs, focused on targeted
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More information5/1/2017. Sexually Transmitted Diseases Burning Questions
Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial
More informationDepartment of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo , Japan 2
Dermatology Research and Practice Volume 2010, Article ID 931340, 5 pages doi:10.1155/2010/931340 Case Report Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid
More informationSkin Manifestations of Drug Reactions
Skin Manifestations of Drug Reactions Dr Carol Hlela, Division of Dermatology Department of Medicine, University of Cape Town and Red Cross Children s Hospital What are the Skin Manifestations of Drug
More informationGynaecology. Pelvic inflammatory disesase
Gynaecology د.شيماءعبداألميرالجميلي Pelvic inflammatory disesase Pelvic inflammatory disease (PID) is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis,
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II SESSION 6. Friday, MARCH 18, 2016 STUDENT COPY
MHD II, Session 6, STUDENT Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION 6 Friday, MARCH 18, 2016 STUDENT COPY Resource for cases: ACP Medicine (Scientific American Medicine) - Vaginitis
More informationEtanercept for Treatment of Hidradenitis
Home Search Browse Resources Help What's New About Purpose Etanercept for Treatment of Hidradenitis This study is currently recruiting patients. Sponsors and Collaborators: University of Pennsylvania Amgen
More informationB. Autoimmune blistering diseases
Go Back to the Top To Order, Visit the Purchasing Page for Details formation immediately above the basal layer. The dermal papillae, which are covered by basal cells in the single layer that is left in
More informationAdvances in STI diagnostics. Dr Paddy Horner Consultant Senior Lecturer University of Bristol
Advances in STI diagnostics Dr Paddy Horner Consultant Senior Lecturer University of Bristol Advances in STI diagnostics Rapid expansion in on-line STI testing Outstripping NHS expert advice Increasing
More informationStevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update
Stevens-Johnson s Syndrome / Toxic Epidermal Necrolysis: An update Robert G. Micheletti, MD Assistant Professor of Dermatology and Medicine Director, Cutaneous Vasculitis Clinic, Penn Vasculitis Center
More informationREGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female
More informationCutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center
Cutaneous Adverse Drug Reactions in Domestic Animals Katherine Doerr, DVM, Dip. ACVD Veterinary Dermatology Center Maitland, Rockledge, Waterford Lakes, FL Not highly studied in veterinary medicine Unknown
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI. Friday, MARCH 20, 2015 STUDENT COPY
MHD II, Session VI, STUDENT Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI Friday, MARCH 20, 2015 STUDENT COPY Resource for cases: ACP Medicine (Scientific American Medicine) - Vaginitis
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationCase 1. Debridement Cultures Keflex Silvadene
The Red Breast Beth McLellan, M.D. Assistant Professor Division of Dermatology Albert Einstein College of Medicine Montefiore Medical Center Jacobi Medical Center Case 1 48 year old radiation oncologist
More informationDERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE
DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON
More informationSexually Transmitted Diseases. Summary of CDC Treatment Guidelines
DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adhesive tape impression 1 Diff Quik in EPD diagnosis, 583 Allergy(ies). See also Food allergy; specific types, e.g., Culicoides hypersensitivity
More informationA Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive Patients
Journal of US-China Medical Science 12 (2015) 85-89 doi: 10.17265/1548-6648/2015.02.008 D DAVID PUBLISHING A Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive
More information4. Behçet s - Treatment
Registered Charity No: 326679 Caring for those with a rare, complex and lifelong disease www.behcets.org.uk 4. Behçet s - Treatment Introduction Because Behçet s Syndrome/Disease is a multisystem disorder,
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationIntroduction to Pemphigoid: Spectrum of Disease & Treatment
Introduction to Pemphigoid: Spectrum of Disease & Treatment A Razzaque Ahmed, MD Center for Blistering Diseases Boston, MA A.Razzaque.Ahmed@tufts.edu centerforblisteringdiseases.com SPECTRUM OF PEMPHIGOID
More informationNothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationUniversity of Groningen. Acantholysis in pemphigus van der Wier, Gerda
University of Groningen Acantholysis in pemphigus van der Wier, Gerda IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationClinical profile of skin diseases in accident and emergency department attenders
Hong Kong J. Dermatol. Venereol. (2007) 15, 4-9 Original Article Clinical profile of skin diseases in accident and emergency department attenders CY Chan, KL Kam, CA Graham, TH Rainer, NM Luk Skin problems
More informationA case of bullous pemphigoid following pemphigus foliaceus
#2228 A case of bullous pemphigoid following pemphigus foliaceus Priyanka Vedak MD 1, Danielle Levine MD 1,3, Lyn Duncan MD 2,3, Hensin Tsao 1,3, Daniela Kroshinsky MD MPH 1,3 1. Department of Dermatology,
More informationClinical spectrum and therapeutic approach in pemphigus vulgaris
Clinical spectrum and therapeutic approach in pemphigus vulgaris Michael Hertl Department of Dermatology and Allergology Philipps University, Marburg, Germany F125: Bullous Diseases: Diagnostic and Management
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationImmunotherapies. Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting.
Immunotherapies Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting. INDEX Select a topic below for more information Principles of immunotherapy Classes
More informationDrugs for UTIs and STDs. Dr.Vishaal Bhat Associate Professor MMMC Manipal
Drugs for UTIs and STDs Dr.Vishaal Bhat Associate Professor MMMC Manipal Classification of UTI s Clinical: Asymptomatic (98%) Symptomatic (1-2%) Anatomical: Lower tract dis: asymptomatic bacteriuria and
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCutaneous Conditions Associated with Systemic Disease
Cutaneous Conditions Associated with Systemic Disease Johnnie M Woodson, M.D., F.A.A.D. Assistant Professor of Dermatology University of Nevada School of Medicine Director of J. Woodson Dermatology & Associates,
More informationPrincipi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile Grand rounds. Lorenzo Cerroni, Graz
Principi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile 2018 Grand rounds Lorenzo Cerroni, Graz "Computer palms" Described in patient using computer keyboards for long periods; similar features described
More informationSTIs- REVISION. Prof A A Hoosen
STIs- REVISION Prof A A Hoosen Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria and the NHLS Microbiology Tertiary Laboratory at the Pretoria Academic Hospital Complex
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationDual Therapy: Symptoms and Screening:
5. Gonorrhea Gonorrhea is caused by Neisseria gonorrhoeae, a bacterium that can grow and multiply in the warm, moist areas of the reproductive tract, including the cervix (opening to the womb), uterus
More informationOverview of Immunotherapy Related Adverse Event (irae) Management
Overview of Immunotherapy Related Adverse Event (irae) Management DR. ROLAND LEUNG MEDICAL ONCOLOGY DEPARTMENT OF MEDICINE THE UNIVERSITY OF HONG KONG QUEEN MARY HOSPITAL Outline Immune system overview
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationNeisseria gonorrhoeae: The Ontario perspective. Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015
Neisseria gonorrhoeae: The Ontario perspective Michael Whelan and Dr. Vanessa Allen PHO Grand Rounds, May 5, 2015 Objectives Participants will be able to: Describe preferred specimen collection for testing
More informationTAO-Cancer Toxicity Management: Cutaneous Toxicities of Immunotherapies
TAO-Cancer Toxicity Management: Cutaneous Toxicities of Immunotherapies Mario E Lacouture MD Director, Oncodermatology Program Attending, Dermatology www. MSKCC.org Dermatologic Care With Immunotherapies
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationIMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical
Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical Guidelines Flebogamma IVIG Per Medical Guidelines Gammagard IVIG/SCIG Per Medical Guidelines
More informationDr Edward Coughlan. Clinical Director Christchurch Sexual Health Christchurch
Dr Edward Coughlan Clinical Director Christchurch Sexual Health Christchurch 16:30-17:25 WS #48: Mycoplasma Genitalium - The New Black 17:35-18:30 WS #58: Mycoplasma Genitalium - The New Black (Repeated)
More informationCost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A
Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A Record Status This is a critical abstract of an economic evaluation that meets the
More informationPemphigus in younger age group in Bangladeshi population
ORIGINAL ARTICLE in younger age group in Bangladeshi population Abdul Wahab 1, MD, Lubna Khondker 1, MD, Jamal Uddin 1, MD, Ishrat Bhuiyan 2, MD Shirajul Islam Khan 3, MD, Zafrul Islam 1, MD, Rahmat Ali
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationToward global prevention of sexually transmitted infections: the need for STI vaccines
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS Toward global prevention of sexually transmitted infections: the need for STI vaccines
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationSexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
More informationCurrent concepts of autoimmune bullous diseases Advances in pathogenesis. Luca Borradori
Current concepts of autoimmune bullous diseases Advances in pathogenesis Luca Borradori Dept. of Dermatology Inselspital, University Hospital of Berne Switzerland Luca.Borradori@insel.ch Autoimmune bullous
More informationClinical Pearls Infectious Diseases. Pritish K. Tosh, MD MN ACP Nov 7, [Answers and discussion slides will be posted after the meeting]
Clinical Pearls Infectious Diseases Pritish K. Tosh, MD MN ACP Nov 7, 2014 [Answers and discussion slides will be posted after the meeting] Case 1 A 33-year-old male with diffuse large B-cell lymphoma
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationBullous Pemphigoid with Lymphocytic Colitis: A Case Report and Short Literature Review
Dermatol Ther (Heidelb) (2016) 6:437 441 DOI 10.1007/s13555-016-0135-4 CASE REPORT Bullous Pemphigoid with Lymphocytic Colitis: A Case Report and Short Literature Review Alexandra Sperl. Johann W. Bauer.
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More informationPelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011
Pelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011 This talk What is Pelvic Inflammatory Disease? Why it is important How it is spread Diagnosis Treatment Prevention What is PID? Inflammation
More informationObjectives. Routine to Rare: Complex Wound and Skin Conditions 8/29/2017
Routine to Rare: Complex Wound and Skin Conditions Debbie Harrell RN, MSN Objectives Describe various pediatric complex wound and skin conditions. Identify the root causes of complex wound and skin conditions
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationDRAFT FOR PUBLIC CONSULTATION. Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa
Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over,
More informationTimby/Smith: Introductory Medical-Surgical Nursing, 9/e
Timby/Smith: Introductory Medical-Surgical Nursing, 9/e Chapter 62: Caring for Clients With Sexually Transmitted Diseases Slide 1 Epidemiology Introduction Study of the occurrence, distribution, and causes
More informationCases of Non-Infectious Vulvovaginitis
Cases of Non-Infectious Vulvovaginitis 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology
More informationWhat's the problem? - click where appropriate.
STI Tool v 1.9 @ 16/11/2017 What's the problem? - click where appropriate. Male problems: screening urethral symptoms proctitis in gay men lumps or swellings ulcers or sores skin rash and/or itch Female
More informationChapter 11. Sexually Transmitted Diseases
Chapter 11. Sexually Transmitted Diseases General Guidelines Persons identified as having one sexually transmitted disease (STD) are at risk for others and should be screened as appropriate. Partners of
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationDiseases of the vulva
Diseases of the vulva 1. Bartholin Cyst - Infection of the Bartholin gland produces an acute inflammation within the gland (adenitis) and may result in an abscess. Bartholin duct cysts - Are relatively
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationDermatology Pearls and News Flash ACP Utah Chapter Scientific Meeting 2017
Dermatology Pearls and News Flash ACP Utah Chapter Scientific Meeting 2017 Christopher M Hull, MD University of Utah School of Medicine Christopher.hull@hsc.utah.edu Conflict of interest No conflicts to
More informationRituximab in refractory autoimmune bullous diseases
Clinical dermatology Review article doi: 10.1111/j.1365-2230.2006.02151.x Rituximab in refractory autoimmune bullous diseases E. Schmidt, N. Hunzelmann,* D. Zillikens, E.-B. Bröcker and M. Goebeler Departments
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationBachelor of Chinese Medicine ( ) AUTOIMMUNE DISEASES
Bachelor of Chinese Medicine (2002 2003) BCM II Dr. EYT Chan February 6, 2003 9:30 am 1:00 pm Rm 134 UPB AUTOIMMUNE DISEASES 1. Introduction Diseases may be the consequence of an aberrant immune response,
More information